Companies · RMD
ResMed
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Aug 17, 2026
ResMed replaces auditor (KPMG to PwC); appoints Carol Burt as Lead Director.
ResMed dismissed KPMG as its independent auditor effective August 13, 2026, following a competitive review, and appointed PricewaterhouseCoopers LLP as the new auditor for fiscal year 2027. The company's Audit Committee found no disagreements or reportable events with KPMG during the prior two years. Separately, director Ronald Taylor announced his retirement from the Board effective the November 2026 annual meeting after 21 years of service; Carol Burt, Nominating and Governance Chair since 2013, was appointed Lead Director effective November 15, 2026.
Tone: neutralRevenue
$5.7B
RMD 10-K · FY 2026
Employees
11,370
Revenue growth YoY
+10%
Founded
1989
Profile
RMD 10-K Item 1 · Aug 13, 2026ResMed is a global leader in digital health and cloud-connected medical devices, focused on sleep apnea, chronic respiratory disease, and home-based care. The company designs AI-powered devices, diagnostic tools, mask systems, and cloud software platforms that enable remote patient monitoring and therapy management. It also provides residential care software to HME, home health, hospice, skilled nursing, and senior living providers.
Read filing description ↓ Collapse description ↑
We are a global leader in digital health and cloud-connected medical devices. We design innovative technology to empower people to live happier, healthier lives. Our artificial intelligence, or AI, powered digital health solutions, cloud-connected devices and intelligent software are designed to make home healthcare more personalized, accessible and effective. By enabling better care, our products improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems. Following our formation in 1989, we commercialized a continuous positive airway pressure, or CPAP, treatment for obstructive sleep apnea, or OSA, which was the first successful non-invasive treatment for OSA. Since the development of CPAP, we have expanded our business by developing or acquiring a number of innovative products and solutions for a broad range of sleep and related breathing health disorders including technologies to be applied in medical and consumer products, life support and ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, and dental devices. In addition, we are a leading provider of cloud-based health applications, software and devices designed to provide connected care, enabling clinicians to manage more patients efficiently and effectively, as well as enabling and encouraging patients' long-term adherence to and satisfaction with their therapy. We also provide management software that assists providers to operate more effectively and efficiently across various residential care settings. We employ approximately 11,370 people and sell our products in more than 140 countries through a combination of wholly owned subsidiaries and independent distributors.
Primary products
- AirSense 11 AutoSet
- AirSense 11 CPAP
- AirSense 10 AutoSet
- AirCurve 11 VAuto
- AirCurve 11 ASV
- AirCurve 10 VAuto
Business segments
End markets
Geographies
Named competitors
“We are the leader in developing smaller, quieter, more comfortable and more connected products.” Competitive position, as stated in the filing
Revenue commentary · FY 2026
Net revenue increased $507 million, or 10% (8% on a constant currency basis), driven by growth in both Sleep and Breathing Health and Residential Care Software segments.
The rest of RMD is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.